Fecal Microbiome Signature Detects Cirrhosis in Nonalcoholic Fatty-Liver Disease Fecal Microbiome Signature Detects Cirrhosis in Nonalcoholic Fatty-Liver Disease

A fecal microbiome signature accurately detects cirrhosis in patients with nonalcoholic fatty-liver disease (NAFLD), researchers report.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Related Links:

As has recently been highlighted in the Journal of Hepatology and elsewhere, patients with liver diseases such as non-alcoholic fatty liver disease (NAFLD) or cirrhosis, as well as liver transplant recipients, carry a high risk of morbidity and mortality due to coronavirus disease 2019 (COVID-19) [1-3]. Many of these patients have additional comorbidities including obesity, diabetes, hypertension, and cardiovascular disease, which are emerging as key predictors of COVID-19 severity [4, 5]. Inflammation and T-cell immune dysregulation are also associated with poor COVID-19 outcomes [6].
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research
Non-alcoholic fatty liver disease (NAFLD) is comprised of a spectrum of liver injury ranging from excess fat accumulation in the liver (steatosis), to steatohepatitis (NASH), to its end stage of cirrhosis. A hallmark of NAFLD progression is the decline in function of hepatic mitochondria, although the mechanisms remain unresolved. Given the important role endothelial nitric oxide synthase (eNOS) plays in mitochondrial dynamics in other tissues, it has emerged as a potential mediator of maintaining mitochondrial function in the liver. In this mini review, we summarize the most relevant findings that extends current understa...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
CONCLUSION: Periodontal disease and tooth loss are positively associated with liver diseases including NAFLD, elevated transaminase level, liver cirrhosis and liver cancer. PMID: 32621350 [PubMed - as supplied by publisher]
Source: Journal of Clinical Periodontology - Category: Dentistry Authors: Tags: J Clin Periodontol Source Type: research
Nonalcoholic fatty liver disease (NAFLD) is typically associated with obesity. Little is known about the prevalence of cirrhosis in patients with NAFLD and a normal body mass index (BMI).
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research
Authors: Lefere S, Devisscher L, Geerts A Abstract Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and an increasing cause of liver cirrhosis and hepatocellular carcinoma. Angiogenesis, the formation of new blood vessels from pre-existing ones, is a key pathophysiological mechanism contributing to NAFLD progression. Major triggers for angiogenesis in NAFLD include tissue hypoxia, structural and dynamic endothelial cell dysfunction, stellate cell activation and macrophage-mediated inflammation. In turn, angiogenesis drives inflammation and is closely linked to the progression...
Source: Acta Gastro-Enterologica Belgica - Category: Gastroenterology Tags: Acta Gastroenterol Belg Source Type: research
Authors: Chiang H, Lu HF, Chen JC, Chen YH, Sun HT, Huang HC, Tien HH, Huang C Abstract Nonalcoholic fatty liver disease (NAFLD) is common worldwide and closely associated with metabolic dysfunction. NAFLD leads to a higher risk of development of severe liver diseases, such as nonalcoholic steatohepatitis (NASH), liver cirrhosis, and hepatocellular carcinoma (HCC). To date, no pharmacotherapy targeting NAFLD has received general approval. Adlay is a plant that has been used as traditional herbal medicine in Asia and is a promising candidate to solve this global issue. We have established a mouse model of NAFLD by f...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Abstract Nonalcoholic fatty liver disease (NAFLD) has become the most prevalent liver disease worldwide. NAFLD is tightly linked to the metabolic syndrome, insulin resistance and oxidative stress. Globally, its inflammatory form, nonalcoholic steatohepatitis (NASH), has become the main cause of liver related morbidity and mortality, mainly due to liver cirrhosis and primary liver cancer. One hallmark of NASH are changes in mitochondrial morphology and function that are accompanied by a blocked flow of electrons in the respiratory chain, which increases formation of mitochondrial reactive oxygen species in a self-p...
Source: American Journal of Physiology. Gastrointestinal and Liver Physiology - Category: Physiology Authors: Tags: Am J Physiol Gastrointest Liver Physiol Source Type: research
Conclusions: NAFLD-related HCCs were more often detected at an advanced stage with infiltrative patterns, although they showed no significant difference in survival compared to ALD-related or HBV-related HCCs. A future prospective research should be focused on identifying NAFLD patients who require strict surveillance in order to early detect and timely treat HCC. PMID: 32566546 [PubMed - in process]
Source: Canadian Journal of Gastroenterology - Category: Gastroenterology Tags: Can J Gastroenterol Hepatol Source Type: research
Abstract Dysregulation of the gut microbiome has been implicated in the progression of non-alcoholic fatty liver disease (NAFLD) to advanced fibrosis and cirrhosis. To determine the diagnostic capacity of this association, we compared stool microbiomes across 163 well-characterized participants encompassing non-NAFLD controls, NAFLD-cirrhosis patients, and their first-degree relatives. Interrogation of shotgun metagenomic and untargeted metabolomic profiles by using the random forest machine learning algorithm and differential abundance analysis identified discrete metagenomic and metabolomic signatures that were ...
Source: Cell Metabolism - Category: Cytology Authors: Tags: Cell Metab Source Type: research
Hepatoprotective effects of ZLY16, a dual peroxisome proliferator-activated receptor α/δ agonist, in rodent model of nonalcoholic steatohepatitis. Eur J Pharmacol. 2020 Jun 24;:173300 Authors: Zhou Z, Deng L, Hu L, Ren Q, Cai Z, Wang B, Li Z, Zhang L Abstract Nonalcoholic fatty liver disease (NAFLD), a chronic progressive liver disease, covers a series of liver damage encompassing steatosis, nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis. However, there are no approved therapies for NAFLD. Herein, we characterize the pharmacological profile of ZLY16 ((E)-2-(4-(3-(2,3-dihydrobe...
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharmacol Source Type: research
More News: Cirrhosis | Fatty Liver Disease (FLD) | Gastroenterology | Health | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Urology & Nephrology